Source: Eur Respir J, 54 (6) 1900857; 10.1183/13993003.00857-2019
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
John G. Elliot, Graham M. Donovan, Kimberley C.W. Wang, Francis H.Y. Green, Alan L. James, Peter B. Noble. Fatty airways: implications for obstructive disease. Eur Respir J, 54 (6) 1900857; 10.1183/13993003.00857-2019

Member's Comments

No comment yet.

Related content which might interest you: Mechanisms in chronic obstructive pulmonary disease: comparisons with asthma Source: Annual Congress 2008 - PG17 - An expert view of the differences between asthma and COPD Year: 2008 Non-alcoholic fatty liver disease (NAFLD): A new mechanism for co-morbidities in chronic obstructive pulmonary disease (COPD)? Source: International Congress 2016 – Recent high impact findings regarding COPD comorbidities Year: 2016 Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease Source: Eur Respir J, 49 (6) 1601923; 10.1183/13993003.01923-2016 Year: 2017 Lymphangiogenesis in chronic obstructive pulmonary disease (COPD): New insights in airways remodeling Source: Annual Congress 2010 - Airways and lung mechanics in subjects of all ages Year: 2010 Immunological profiling of chronic obstructive airways disease and idiopathic pulmonary fibrosis Source: Virtual Congress 2020 – Novel immunopathological mechanisms of lung disease: knowledge from translational studies Year: 2020 Accelerated ageing and chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2003 - Cigarette smoke: how it does its dirty work Year: 2003 Regulation disorders of pulmonary lipid metabolism in chronic obstructive pulmonary disease Source: International Congress 2019 – Research and innovation in airway diseases Year: 2019 Chronic obstructive pulmonary disease and tuberculosis: phenotypes, options Source: Virtual Congress 2020 – Tuberculosis and comorbidities Year: 2020 Features of the bronchial mucosa in heavy smokers with and without chronic obstructive pulmonary disease Source: International Congress 2015 – COPD: interesting notes Year: 2015 Introduction: systemic effects in chronic obstructive pulmonary disease Source: Eur Respir J 2003; 22: 1S Year: 2003 The lung microbiome in obstructive airways disease: potential pathogenetic roles Source: Eur Respir Monogr 2019; 83: 140-157 Year: 2019 Therapeutic responses in asthma and chronic obstructive pulmonary disease Source: Annual Congress 2008 - PG17 - An expert view of the differences between asthma and COPD Year: 2008 Therapeutic approaches in the chronic obstructive (COPD) pulmonary disease Source: Eur Respir J 2002; 20: Suppl. 38, 472s Year: 2002 The metabolic syndrome in patients with chronic obstructive pulmonary disease Source: International Congress 2014 – The assessment of comorbidities Year: 2014 Chronic obstructive pulmonary disease: the patient perspective Source: Eur Respir J 2001; 18: Suppl. 33, 401s Year: 2001 Inflammation and depression in chronic obstructive pulmonary disease Source: Eur Respir J 2007; 30: Suppl. 51, 718s Year: 2007 Chronic obstructive pulmonary disease (COPD) – patient‘s perspective Source: Eur Respir J 2007; 30: Suppl. 51, 168s Year: 2007 Revisited role for mucus hypersecretion in the pathogenesis of COPD Source: Eur Respir Rev 2009; 19: 109-112 Year: 2010 Mechanisms of ECG changes in chronic obstructive pulmonary disease Source: International Congress 2016 – Pulmonary hypertension in lung disease Year: 2016 Chronic obstructive pulmonary disease (COPD) patients with bronchiectasis: clinical features? Source: International Congress 2018 – COPD exacerbations and bronchiectasis Year: 2018